Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial

What Was Tested

This randomized controlled trial paper looks at Octreotide and Vasopressin.

Tolvaptan and octreotide-long-acting release (LAR) have renoprotective effects in autosomal dominant polycystic kidney disease (ADPKD) that are partially mediated by amelioration of compensatory glomerular hyperfiltration.

The researchers compared the effects of tolvaptan and octreotide-LAR combination therapy versus those of tolvaptan monotherapy in patients with ADPKD.

Who Took Part

The study group was 19 patients.

How the Study Was Run

The design is described as randomized, placebo-controlled, crossover and pilot.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

Some patients received a placebo instead of Octreotide, giving a reference point.

In the crossover set-up each of the patients took both Octreotide and the comparison in turn, acting as their own control.

It is described as a pilot, a small early test of whether a larger Octreotide study would be practical.

The local ethical committee approved the study.

What Was Measured

Topics PubMed links to this paper include Tolvaptan, Polycystic Kidney, Autosomal Dominant, Octreotide, Kidney and Antidiuretic Hormone Receptor Antagonists.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Octreotide and Vasopressin in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Octreotide compound page and the Vasopressin compound page, all human trials.